Denali Therapeutics (DNLI) Cash from Investing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Investing Activities data on file, last reported at $94.5 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $94.5 million, up 403.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $331.0 million (down 13.62% YoY), and the FY2025 annual result was $255.3 million, up 387.62% from the prior year.
• Cash from Investing Activities rose to $94.5 million in Q1 2026 per DNLI's latest filing, from $20.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $172.2 million in Q4 2024 and troughed at -$453.2 million in Q1 2024.
• A 5-year average of $21.7 million and a median of $73.0 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 554.45% in 2023, then sank 388.8% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$127.6 million in 2022, then jumped by 157.27% to $73.0 million in 2023, then surged by 135.75% to $172.2 million in 2024, then slumped by 87.94% to $20.8 million in 2025, then soared by 354.83% to $94.5 million in 2026.
• Business Quant data shows DNLI's Cash from Investing Activities at $94.5 million in Q1 2026, $20.8 million in Q4 2025, and $57.8 million in Q3 2025.